Results 131 to 140 of about 2,600,404 (289)
Organoid Brain‐Machine‐Interface Devices for Central Nervous System Repair
We envision organoid brain‐machine‐interface (Organoid‐BMI) devices as new biohybrid bidirectional communication pathways to connect the human CNS and the external world for personalized CNS repair and regeneration. ABSTRACT Central nervous system (CNS) repair and regeneration suffer from tremendous clinical challenges due to current limitations in ...
Yantao Xing +10 more
wiley +1 more source
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen +22 more
wiley +1 more source
A fully synthetic four‐component vaccine has been developed combining Tn antigen, vizantin (Mincle agonist), rhamnose (antibody recruitment), and mannose (CD206 targeting). By synergistically activating Mincle, FcγR, and CD206 pathways, it elicits strong IgG switching and cytotoxic T‐cells, significantly inhibiting tumors in mice.
Wenbo Ming +9 more
wiley +1 more source
Expanding the circles across outdoor learning and acceptance commitment therapy in schools
The interdisciplinary research presented in this workshop highlights the synergies between outdoor learning and a therapeutic intervention grounded in Acceptance Commitment Therapy (ACT).
Gray, Tonia (R16988) +3 more
core
A bismuth–copper diselenide–based nanoplatform (BSCS@PHY) coordinates immunogenic cell death with local A2A receptor blockade in 4T1 tumors. Thermally triggered shell melting exposes catalytic surfaces for glutathione depletion and chemodynamic ROS generation, while co‐delivering an A2AR antagonist and yeast‐wall adjuvant to enhance dendritic‐cell ...
Xiangting Yi +12 more
wiley +1 more source
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo +16 more
wiley +1 more source
Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. [PDF]
Chen T +11 more
europepmc +1 more source
IntroductionTreatment of hypersensitivity pneumonitis involves removal of the antigen and may include the use of immunosuppression or antifibrotic therapy.
Margaret Kypreos +6 more
doaj +1 more source
Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten +30 more
wiley +1 more source
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao +7 more
wiley +1 more source

